Labcorp | Spokane

110 W Cliff Dr 100-200, Spokane, WA 99204

State Toll-free Telephone: (800) 349-8586

Kyle Strickland, MD, PhD

Dr. Strickland is board-certified in Anatomic Pathology and Cytopathology.  He graduated from the NIH-funded Medical Scientist Training Program at the Medical University of South Carolina. He performed his Ph.D. research on the enzymatic pathways of folate biochemistry, and he completed residency in Anatomic Pathology, followed by sub-specialty fellowship training in Cytopathology and Gynecologic Pathology, at Brigham and Women’s Hospital, Harvard Medical School. Prior to joining our team, Dr.

Eric Severson, MD, PhD, MMSc

Dr. Eric Severson is a board-certified anatomic and hematopathologist with expertise in hematologic malignancies, molecular pathology, computational biology, comprehensive genomic profiling, and precision medicine.  Dr. Severson earned his M.D. and Ph.D. in molecular biology and genetics from Emory University Medical School and Graduate School of Biomedical Sciences, followed by residency training at Brigham and Women’s Hospital.

Shakti Ramkissoon, MD, PhD

Dr. Shakti Ramkissoon is board certified in anatomic pathology and neuropathology with expertise in adult and pediatric brain tumors. He obtained his MD/PhD from Rutgers -- New Jersey Medical School, concentrating on cancer stem cell biology. Dr. Ramkissoon then completed an anatomic pathology residency and neuropathology fellowship training at Brigham and Women's Hospital (BWH), Boston, Mass. After completing his clinical training, Dr.

<span>Labcorp announces 2022 fourth quarter and full-year results</span>
February 16, 2023

Labcorp announces 2022 fourth quarter and full-year results

Company Provides 2023 Guidance Revenue: Q4 of $3.7 billion , versus $4.1 billion last year; Full year of $14.9 billion , versus $16.1 billion last year Diluted EPS: Q4 of $0.86 , versus $5.75 last year; Full year of $13.97 , versus $24.39 last year Adjusted EPS: Q4 of $4.14 , versus $6.77 last

Rebecca Previs, MD, MS

Dr. Rebecca Previs is a board-certified gynecologic oncologist with expertise in women’s health, precision medicine and early phase clinical trials. Dr. Previs prioritizes her research in evaluating the immune contexture of molecular characterized uterine cancers and how biomarkers can inform prognosis and treatment response in patients with medically managed uterine cancers.

Heidi Ko, DO

Dr. Heidi Ko is board certified in Internal Medicine, Hematology and Medical Oncology.  She received her medical degree from Rowan University School of Osteopathic Medicine in Stratford, NJ and her Internal Medicine training at McGovern Medical School at UT Health in Houston, TX.  Dr. Ko completed her Hematology and Oncology fellowship training at Montefiore Medical Center/Albert Einstein College of Medicine in Bronx, NY. After her fellowship, Dr.